nodes	percent_of_prediction	percent_of_DWPC	metapath
Zoledronate—ABCC1—Epirubicin—urinary bladder cancer	0.168	0.354	CbGbCtD
Zoledronate—ABCC1—Etoposide—urinary bladder cancer	0.131	0.276	CbGbCtD
Zoledronate—ABCC1—Doxorubicin—urinary bladder cancer	0.0894	0.188	CbGbCtD
Zoledronate—ABCC1—Methotrexate—urinary bladder cancer	0.0866	0.182	CbGbCtD
Zoledronate—GGPS1—prostate gland—urinary bladder cancer	0.0123	0.0924	CbGeAlD
Zoledronate—GGPS1—seminal vesicle—urinary bladder cancer	0.0104	0.0781	CbGeAlD
Zoledronate—GGPS1—renal system—urinary bladder cancer	0.00837	0.063	CbGeAlD
Zoledronate—GGPS1—urethra—urinary bladder cancer	0.00822	0.0619	CbGeAlD
Zoledronate—CA14—prostate gland—urinary bladder cancer	0.00734	0.0552	CbGeAlD
Zoledronate—GGPS1—female reproductive system—urinary bladder cancer	0.00671	0.0504	CbGeAlD
Zoledronate—FDPS—SREBP signalling—AMFR—urinary bladder cancer	0.00638	0.109	CbGpPWpGaD
Zoledronate—CA14—seminal vesicle—urinary bladder cancer	0.00621	0.0467	CbGeAlD
Zoledronate—GGPS1—vagina—urinary bladder cancer	0.00606	0.0456	CbGeAlD
Zoledronate—FDPS—prostate gland—urinary bladder cancer	0.00566	0.0426	CbGeAlD
Zoledronate—FDPS—seminal vesicle—urinary bladder cancer	0.00479	0.036	CbGeAlD
Zoledronate—FDPS—smooth muscle tissue—urinary bladder cancer	0.00401	0.0302	CbGeAlD
Zoledronate—GGPS1—lymph node—urinary bladder cancer	0.00392	0.0295	CbGeAlD
Zoledronate—CA12—renal system—urinary bladder cancer	0.0039	0.0294	CbGeAlD
Zoledronate—FDPS—renal system—urinary bladder cancer	0.00386	0.029	CbGeAlD
Zoledronate—FDPS—urethra—urinary bladder cancer	0.00379	0.0285	CbGeAlD
Zoledronate—ABCC1—prostate gland—urinary bladder cancer	0.00329	0.0247	CbGeAlD
Zoledronate—CA12—female reproductive system—urinary bladder cancer	0.00313	0.0235	CbGeAlD
Zoledronate—FDPS—female reproductive system—urinary bladder cancer	0.00309	0.0232	CbGeAlD
Zoledronate—CA2—prostate gland—urinary bladder cancer	0.00294	0.0221	CbGeAlD
Zoledronate—FDPS—vagina—urinary bladder cancer	0.0028	0.021	CbGeAlD
Zoledronate—ABCC1—Synthesis of Leukotrienes (LT) and Eoxins (EX)—CYP4B1—urinary bladder cancer	0.00279	0.0477	CbGpPWpGaD
Zoledronate—ABCC1—seminal vesicle—urinary bladder cancer	0.00278	0.0209	CbGeAlD
Zoledronate—ABCC1—Cobalamin (Cbl, vitamin B12) transport and metabolism—PRSS3—urinary bladder cancer	0.00267	0.0457	CbGpPWpGaD
Zoledronate—CA2—seminal vesicle—urinary bladder cancer	0.00249	0.0187	CbGeAlD
Zoledronate—GGPS1—Activation of gene expression by SREBF (SREBP)—CREBBP—urinary bladder cancer	0.00247	0.0423	CbGpPWpGaD
Zoledronate—ABCC1—urethra—urinary bladder cancer	0.0022	0.0166	CbGeAlD
Zoledronate—CA2—epithelium—urinary bladder cancer	0.00216	0.0162	CbGeAlD
Zoledronate—CA2—smooth muscle tissue—urinary bladder cancer	0.00208	0.0157	CbGeAlD
Zoledronate—CA2—renal system—urinary bladder cancer	0.002	0.0151	CbGeAlD
Zoledronate—GGPS1—Regulation of cholesterol biosynthesis by SREBP (SREBF)—CREBBP—urinary bladder cancer	0.00197	0.0338	CbGpPWpGaD
Zoledronate—Risedronate—PTGS2—urinary bladder cancer	0.00181	0.529	CrCbGaD
Zoledronate—FDPS—lymph node—urinary bladder cancer	0.00181	0.0136	CbGeAlD
Zoledronate—ABCC1—vagina—urinary bladder cancer	0.00162	0.0122	CbGeAlD
Zoledronate—Clodronate—PTGS2—urinary bladder cancer	0.00162	0.471	CrCbGaD
Zoledronate—CA2—female reproductive system—urinary bladder cancer	0.0016	0.0121	CbGeAlD
Zoledronate—CA2—vagina—urinary bladder cancer	0.00145	0.0109	CbGeAlD
Zoledronate—ABCC1—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00139	0.0238	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00131	0.0224	CbGpPWpGaD
Zoledronate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—GSTO2—urinary bladder cancer	0.00109	0.0186	CbGpPWpGaD
Zoledronate—FDPS—Activation of gene expression by SREBF (SREBP)—CREBBP—urinary bladder cancer	0.00106	0.0181	CbGpPWpGaD
Zoledronate—ABCC1—lymph node—urinary bladder cancer	0.00105	0.0079	CbGeAlD
Zoledronate—CA2—lymph node—urinary bladder cancer	0.000939	0.00706	CbGeAlD
Zoledronate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—urinary bladder cancer	0.000845	0.0145	CbGpPWpGaD
Zoledronate—FDPS—Regulation of cholesterol biosynthesis by SREBP (SREBF)—CREBBP—urinary bladder cancer	0.000843	0.0144	CbGpPWpGaD
Zoledronate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PRSS3—urinary bladder cancer	0.000823	0.0141	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—GSTZ1—urinary bladder cancer	0.000745	0.0128	CbGpPWpGaD
Zoledronate—ABCC1—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000741	0.0127	CbGpPWpGaD
Zoledronate—FDPS—SREBP signalling—PPARG—urinary bladder cancer	0.00071	0.0122	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—GSTO2—urinary bladder cancer	0.000707	0.0121	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—NAT1—urinary bladder cancer	0.000707	0.0121	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000695	0.0119	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—UGT2B7—urinary bladder cancer	0.000646	0.0111	CbGpPWpGaD
Zoledronate—ABCC1—S1P1 pathway—RHOA—urinary bladder cancer	0.000618	0.0106	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—CYP4B1—urinary bladder cancer	0.000582	0.00996	CbGpPWpGaD
Zoledronate—ABCC1—S1P1 pathway—PTGS2—urinary bladder cancer	0.00056	0.00957	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000558	0.00954	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—SLC19A1—urinary bladder cancer	0.00055	0.0094	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—PRSS3—urinary bladder cancer	0.000536	0.00916	CbGpPWpGaD
Zoledronate—ABCC1—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000438	0.0075	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000429	0.00735	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—TYMP—urinary bladder cancer	0.000428	0.00733	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000411	0.00704	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—NAT2—urinary bladder cancer	0.000387	0.00663	CbGpPWpGaD
Zoledronate—CA14—Metabolism—GSTZ1—urinary bladder cancer	0.000364	0.00623	CbGpPWpGaD
Zoledronate—CA14—Metabolism—GSTO2—urinary bladder cancer	0.000345	0.00591	CbGpPWpGaD
Zoledronate—CA14—Metabolism—NAT1—urinary bladder cancer	0.000345	0.00591	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—RRM2—urinary bladder cancer	0.000334	0.00572	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—GSTZ1—urinary bladder cancer	0.000318	0.00544	CbGpPWpGaD
Zoledronate—CA14—Metabolism—UGT2B7—urinary bladder cancer	0.000316	0.0054	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—ENO2—urinary bladder cancer	0.00031	0.0053	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—HPGDS—urinary bladder cancer	0.00031	0.0053	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000308	0.00527	CbGpPWpGaD
Zoledronate—CA12—Metabolism—GSTZ1—urinary bladder cancer	0.000307	0.00525	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—NAT1—urinary bladder cancer	0.000302	0.00516	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—GSTO2—urinary bladder cancer	0.000302	0.00516	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—GSTT1—urinary bladder cancer	0.0003	0.00514	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000297	0.00508	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000296	0.00506	CbGpPWpGaD
Zoledronate—CA12—Metabolism—GSTO2—urinary bladder cancer	0.000291	0.00498	CbGpPWpGaD
Zoledronate—CA12—Metabolism—NAT1—urinary bladder cancer	0.000291	0.00498	CbGpPWpGaD
Zoledronate—CA14—Metabolism—CYP4B1—urinary bladder cancer	0.000284	0.00486	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—UGT2B7—urinary bladder cancer	0.000276	0.00472	CbGpPWpGaD
Zoledronate—CA14—Metabolism—SLC19A1—urinary bladder cancer	0.000268	0.00459	CbGpPWpGaD
Zoledronate—CA12—Metabolism—UGT2B7—urinary bladder cancer	0.000266	0.00455	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PRSS3—urinary bladder cancer	0.000262	0.00448	CbGpPWpGaD
Zoledronate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.00026	0.00444	CbGpPWpGaD
Zoledronate—ABCC1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000258	0.00442	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—NQO1—urinary bladder cancer	0.00025	0.00427	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—CYP4B1—urinary bladder cancer	0.000248	0.00425	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000242	0.00414	CbGpPWpGaD
Zoledronate—CA12—Metabolism—CYP4B1—urinary bladder cancer	0.00024	0.0041	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—SLC19A1—urinary bladder cancer	0.000235	0.00401	CbGpPWpGaD
Zoledronate—CA2—Metabolism—GSTZ1—urinary bladder cancer	0.000235	0.00401	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.00023	0.00393	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PRSS3—urinary bladder cancer	0.000229	0.00391	CbGpPWpGaD
Zoledronate—CA12—Metabolism—SLC19A1—urinary bladder cancer	0.000226	0.00387	CbGpPWpGaD
Zoledronate—CA2—Metabolism—GSTO2—urinary bladder cancer	0.000222	0.00381	CbGpPWpGaD
Zoledronate—CA2—Metabolism—NAT1—urinary bladder cancer	0.000222	0.00381	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PRSS3—urinary bladder cancer	0.00022	0.00377	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000211	0.00361	CbGpPWpGaD
Zoledronate—CA14—Metabolism—TYMP—urinary bladder cancer	0.000209	0.00358	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—GSTP1—urinary bladder cancer	0.000208	0.00356	CbGpPWpGaD
Zoledronate—CA2—Metabolism—UGT2B7—urinary bladder cancer	0.000203	0.00348	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000201	0.00345	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000199	0.00341	CbGpPWpGaD
Zoledronate—Abdominal pain—Etoposide—urinary bladder cancer	0.000199	0.000602	CcSEcCtD
Zoledronate—Body temperature increased—Etoposide—urinary bladder cancer	0.000199	0.000602	CcSEcCtD
Zoledronate—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000199	0.000602	CcSEcCtD
Zoledronate—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000199	0.000602	CcSEcCtD
Zoledronate—Eye disorder—Methotrexate—urinary bladder cancer	0.000198	0.0006	CcSEcCtD
Zoledronate—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000198	0.0006	CcSEcCtD
Zoledronate—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000197	0.000598	CcSEcCtD
Zoledronate—Asthenia—Cisplatin—urinary bladder cancer	0.000197	0.000596	CcSEcCtD
Zoledronate—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000197	0.000596	CcSEcCtD
Zoledronate—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000196	0.000593	CcSEcCtD
Zoledronate—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000195	0.000592	CcSEcCtD
Zoledronate—Haematuria—Doxorubicin—urinary bladder cancer	0.000195	0.000591	CcSEcCtD
Zoledronate—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000195	0.000591	CcSEcCtD
Zoledronate—Urethral disorder—Epirubicin—urinary bladder cancer	0.000194	0.000589	CcSEcCtD
Zoledronate—GGPS1—Metabolism—TYMS—urinary bladder cancer	0.000193	0.00331	CbGpPWpGaD
Zoledronate—Angiopathy—Methotrexate—urinary bladder cancer	0.000192	0.000583	CcSEcCtD
Zoledronate—Immune system disorder—Methotrexate—urinary bladder cancer	0.000191	0.00058	CcSEcCtD
Zoledronate—Dizziness—Fluorouracil—urinary bladder cancer	0.000191	0.00058	CcSEcCtD
Zoledronate—GGPS1—Metabolism—NCOR1—urinary bladder cancer	0.000191	0.00327	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—GSTM1—urinary bladder cancer	0.000191	0.00327	CbGpPWpGaD
Zoledronate—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000191	0.000579	CcSEcCtD
Zoledronate—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000191	0.000578	CcSEcCtD
Zoledronate—Chills—Methotrexate—urinary bladder cancer	0.00019	0.000576	CcSEcCtD
Zoledronate—CA14—Metabolism—NAT2—urinary bladder cancer	0.000189	0.00324	CbGpPWpGaD
Zoledronate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000188	0.000569	CcSEcCtD
Zoledronate—Alopecia—Methotrexate—urinary bladder cancer	0.000187	0.000567	CcSEcCtD
Zoledronate—Vomiting—Gemcitabine—urinary bladder cancer	0.000187	0.000567	CcSEcCtD
Zoledronate—Bradycardia—Doxorubicin—urinary bladder cancer	0.000187	0.000566	CcSEcCtD
Zoledronate—Mental disorder—Methotrexate—urinary bladder cancer	0.000186	0.000563	CcSEcCtD
Zoledronate—Rash—Gemcitabine—urinary bladder cancer	0.000186	0.000562	CcSEcCtD
Zoledronate—Dermatitis—Gemcitabine—urinary bladder cancer	0.000185	0.000562	CcSEcCtD
Zoledronate—Eye disorder—Epirubicin—urinary bladder cancer	0.000185	0.000562	CcSEcCtD
Zoledronate—Hypersensitivity—Etoposide—urinary bladder cancer	0.000185	0.000561	CcSEcCtD
Zoledronate—Erythema—Methotrexate—urinary bladder cancer	0.000184	0.000559	CcSEcCtD
Zoledronate—Malnutrition—Methotrexate—urinary bladder cancer	0.000184	0.000559	CcSEcCtD
Zoledronate—Headache—Gemcitabine—urinary bladder cancer	0.000184	0.000559	CcSEcCtD
Zoledronate—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000184	0.000558	CcSEcCtD
Zoledronate—Flushing—Epirubicin—urinary bladder cancer	0.000184	0.000558	CcSEcCtD
Zoledronate—Vomiting—Fluorouracil—urinary bladder cancer	0.000184	0.000558	CcSEcCtD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000183	0.00314	CbGpPWpGaD
Zoledronate—CA2—Metabolism—CYP4B1—urinary bladder cancer	0.000183	0.00313	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—GPX1—urinary bladder cancer	0.000183	0.00313	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—TYMP—urinary bladder cancer	0.000183	0.00313	CbGpPWpGaD
Zoledronate—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000183	0.000553	CcSEcCtD
Zoledronate—Rash—Fluorouracil—urinary bladder cancer	0.000183	0.000553	CcSEcCtD
Zoledronate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000182	0.000552	CcSEcCtD
Zoledronate—Headache—Fluorouracil—urinary bladder cancer	0.000181	0.000549	CcSEcCtD
Zoledronate—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000181	0.000549	CcSEcCtD
Zoledronate—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000181	0.000548	CcSEcCtD
Zoledronate—Dysgeusia—Methotrexate—urinary bladder cancer	0.000181	0.000547	CcSEcCtD
Zoledronate—Asthenia—Etoposide—urinary bladder cancer	0.00018	0.000546	CcSEcCtD
Zoledronate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00018	0.000546	CcSEcCtD
Zoledronate—Angiopathy—Epirubicin—urinary bladder cancer	0.00018	0.000545	CcSEcCtD
Zoledronate—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00018	0.000545	CcSEcCtD
Zoledronate—GGPS1—Metabolism—ERCC2—urinary bladder cancer	0.00018	0.00308	CbGpPWpGaD
Zoledronate—Immune system disorder—Epirubicin—urinary bladder cancer	0.000179	0.000543	CcSEcCtD
Zoledronate—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000179	0.000542	CcSEcCtD
Zoledronate—Back pain—Methotrexate—urinary bladder cancer	0.000178	0.000541	CcSEcCtD
Zoledronate—Chills—Epirubicin—urinary bladder cancer	0.000178	0.000539	CcSEcCtD
Zoledronate—Pruritus—Etoposide—urinary bladder cancer	0.000178	0.000539	CcSEcCtD
Zoledronate—Arrhythmia—Epirubicin—urinary bladder cancer	0.000177	0.000537	CcSEcCtD
Zoledronate—CA12—Metabolism—TYMP—urinary bladder cancer	0.000176	0.00302	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000176	0.003	CbGpPWpGaD
Zoledronate—Alopecia—Epirubicin—urinary bladder cancer	0.000175	0.000531	CcSEcCtD
Zoledronate—Nausea—Gemcitabine—urinary bladder cancer	0.000175	0.00053	CcSEcCtD
Zoledronate—Vomiting—Cisplatin—urinary bladder cancer	0.000174	0.000529	CcSEcCtD
Zoledronate—Vision blurred—Methotrexate—urinary bladder cancer	0.000174	0.000527	CcSEcCtD
Zoledronate—Mental disorder—Epirubicin—urinary bladder cancer	0.000174	0.000526	CcSEcCtD
Zoledronate—Rash—Cisplatin—urinary bladder cancer	0.000173	0.000524	CcSEcCtD
Zoledronate—CA2—Metabolism—SLC19A1—urinary bladder cancer	0.000173	0.00296	CbGpPWpGaD
Zoledronate—Dermatitis—Cisplatin—urinary bladder cancer	0.000173	0.000524	CcSEcCtD
Zoledronate—Malnutrition—Epirubicin—urinary bladder cancer	0.000173	0.000523	CcSEcCtD
Zoledronate—Erythema—Epirubicin—urinary bladder cancer	0.000173	0.000523	CcSEcCtD
Zoledronate—Diarrhoea—Etoposide—urinary bladder cancer	0.000172	0.000521	CcSEcCtD
Zoledronate—Nausea—Fluorouracil—urinary bladder cancer	0.000172	0.000521	CcSEcCtD
Zoledronate—Eye disorder—Doxorubicin—urinary bladder cancer	0.000172	0.00052	CcSEcCtD
Zoledronate—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000171	0.000519	CcSEcCtD
Zoledronate—Anaemia—Methotrexate—urinary bladder cancer	0.000171	0.000517	CcSEcCtD
Zoledronate—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00017	0.000516	CcSEcCtD
Zoledronate—Flushing—Doxorubicin—urinary bladder cancer	0.00017	0.000516	CcSEcCtD
Zoledronate—Dysgeusia—Epirubicin—urinary bladder cancer	0.000169	0.000512	CcSEcCtD
Zoledronate—GGPS1—Metabolism—MTHFR—urinary bladder cancer	0.000169	0.00289	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PRSS3—urinary bladder cancer	0.000169	0.00288	CbGpPWpGaD
Zoledronate—Back pain—Epirubicin—urinary bladder cancer	0.000167	0.000506	CcSEcCtD
Zoledronate—Angiopathy—Doxorubicin—urinary bladder cancer	0.000167	0.000504	CcSEcCtD
Zoledronate—Malaise—Methotrexate—urinary bladder cancer	0.000166	0.000504	CcSEcCtD
Zoledronate—Dizziness—Etoposide—urinary bladder cancer	0.000166	0.000504	CcSEcCtD
Zoledronate—ABCC1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000166	0.00284	CbGpPWpGaD
Zoledronate—Muscle spasms—Epirubicin—urinary bladder cancer	0.000166	0.000503	CcSEcCtD
Zoledronate—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000166	0.000502	CcSEcCtD
Zoledronate—Vertigo—Methotrexate—urinary bladder cancer	0.000166	0.000502	CcSEcCtD
Zoledronate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—urinary bladder cancer	0.000166	0.00283	CbGpPWpGaD
Zoledronate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000165	0.000501	CcSEcCtD
Zoledronate—FDPS—Metabolism—NAT2—urinary bladder cancer	0.000165	0.00283	CbGpPWpGaD
Zoledronate—Leukopenia—Methotrexate—urinary bladder cancer	0.000165	0.0005	CcSEcCtD
Zoledronate—Chills—Doxorubicin—urinary bladder cancer	0.000165	0.000499	CcSEcCtD
Zoledronate—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000164	0.000497	CcSEcCtD
Zoledronate—CA14—Metabolism—RRM2—urinary bladder cancer	0.000163	0.00279	CbGpPWpGaD
Zoledronate—Nausea—Cisplatin—urinary bladder cancer	0.000163	0.000494	CcSEcCtD
Zoledronate—Vision blurred—Epirubicin—urinary bladder cancer	0.000163	0.000493	CcSEcCtD
Zoledronate—Alopecia—Doxorubicin—urinary bladder cancer	0.000162	0.000491	CcSEcCtD
Zoledronate—Cough—Methotrexate—urinary bladder cancer	0.000161	0.000488	CcSEcCtD
Zoledronate—Mental disorder—Doxorubicin—urinary bladder cancer	0.000161	0.000487	CcSEcCtD
Zoledronate—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00016	0.000485	CcSEcCtD
Zoledronate—Convulsion—Methotrexate—urinary bladder cancer	0.00016	0.000484	CcSEcCtD
Zoledronate—Vomiting—Etoposide—urinary bladder cancer	0.00016	0.000484	CcSEcCtD
Zoledronate—Erythema—Doxorubicin—urinary bladder cancer	0.00016	0.000484	CcSEcCtD
Zoledronate—Malnutrition—Doxorubicin—urinary bladder cancer	0.00016	0.000484	CcSEcCtD
Zoledronate—Anaemia—Epirubicin—urinary bladder cancer	0.00016	0.000483	CcSEcCtD
Zoledronate—CA12—Metabolism—NAT2—urinary bladder cancer	0.000159	0.00273	CbGpPWpGaD
Zoledronate—Agitation—Epirubicin—urinary bladder cancer	0.000159	0.000481	CcSEcCtD
Zoledronate—Rash—Etoposide—urinary bladder cancer	0.000158	0.00048	CcSEcCtD
Zoledronate—Dermatitis—Etoposide—urinary bladder cancer	0.000158	0.00048	CcSEcCtD
Zoledronate—Headache—Etoposide—urinary bladder cancer	0.000157	0.000477	CcSEcCtD
Zoledronate—Arthralgia—Methotrexate—urinary bladder cancer	0.000157	0.000476	CcSEcCtD
Zoledronate—Chest pain—Methotrexate—urinary bladder cancer	0.000157	0.000476	CcSEcCtD
Zoledronate—Myalgia—Methotrexate—urinary bladder cancer	0.000157	0.000476	CcSEcCtD
Zoledronate—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000156	0.000474	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000156	0.000473	CcSEcCtD
Zoledronate—Malaise—Epirubicin—urinary bladder cancer	0.000156	0.000472	CcSEcCtD
Zoledronate—Discomfort—Methotrexate—urinary bladder cancer	0.000155	0.00047	CcSEcCtD
Zoledronate—Vertigo—Epirubicin—urinary bladder cancer	0.000155	0.00047	CcSEcCtD
Zoledronate—Syncope—Epirubicin—urinary bladder cancer	0.000155	0.000469	CcSEcCtD
Zoledronate—Leukopenia—Epirubicin—urinary bladder cancer	0.000155	0.000468	CcSEcCtD
Zoledronate—Back pain—Doxorubicin—urinary bladder cancer	0.000155	0.000468	CcSEcCtD
Zoledronate—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000154	0.000465	CcSEcCtD
Zoledronate—Palpitations—Epirubicin—urinary bladder cancer	0.000153	0.000462	CcSEcCtD
Zoledronate—Confusional state—Methotrexate—urinary bladder cancer	0.000152	0.00046	CcSEcCtD
Zoledronate—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000152	0.00046	CcSEcCtD
Zoledronate—CA14—Metabolism—HPGDS—urinary bladder cancer	0.000151	0.00259	CbGpPWpGaD
Zoledronate—CA14—Metabolism—ENO2—urinary bladder cancer	0.000151	0.00259	CbGpPWpGaD
Zoledronate—Cough—Epirubicin—urinary bladder cancer	0.000151	0.000456	CcSEcCtD
Zoledronate—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000151	0.000456	CcSEcCtD
Zoledronate—Vision blurred—Doxorubicin—urinary bladder cancer	0.000151	0.000456	CcSEcCtD
Zoledronate—Convulsion—Epirubicin—urinary bladder cancer	0.00015	0.000453	CcSEcCtD
Zoledronate—Infection—Methotrexate—urinary bladder cancer	0.00015	0.000453	CcSEcCtD
Zoledronate—Nausea—Etoposide—urinary bladder cancer	0.000149	0.000452	CcSEcCtD
Zoledronate—Hypertension—Epirubicin—urinary bladder cancer	0.000149	0.000452	CcSEcCtD
Zoledronate—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000148	0.000449	CcSEcCtD
Zoledronate—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000148	0.000447	CcSEcCtD
Zoledronate—Anaemia—Doxorubicin—urinary bladder cancer	0.000148	0.000447	CcSEcCtD
Zoledronate—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000147	0.000447	CcSEcCtD
Zoledronate—Myalgia—Epirubicin—urinary bladder cancer	0.000147	0.000445	CcSEcCtD
Zoledronate—Chest pain—Epirubicin—urinary bladder cancer	0.000147	0.000445	CcSEcCtD
Zoledronate—Arthralgia—Epirubicin—urinary bladder cancer	0.000147	0.000445	CcSEcCtD
Zoledronate—Agitation—Doxorubicin—urinary bladder cancer	0.000147	0.000445	CcSEcCtD
Zoledronate—CA14—Metabolism—GSTT1—urinary bladder cancer	0.000147	0.00251	CbGpPWpGaD
Zoledronate—Anxiety—Epirubicin—urinary bladder cancer	0.000146	0.000444	CcSEcCtD
Zoledronate—Skin disorder—Methotrexate—urinary bladder cancer	0.000146	0.000443	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000146	0.000442	CcSEcCtD
Zoledronate—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000146	0.000441	CcSEcCtD
Zoledronate—Discomfort—Epirubicin—urinary bladder cancer	0.000145	0.00044	CcSEcCtD
Zoledronate—Malaise—Doxorubicin—urinary bladder cancer	0.000144	0.000436	CcSEcCtD
Zoledronate—Dry mouth—Epirubicin—urinary bladder cancer	0.000144	0.000436	CcSEcCtD
Zoledronate—Vertigo—Doxorubicin—urinary bladder cancer	0.000144	0.000435	CcSEcCtD
Zoledronate—Anorexia—Methotrexate—urinary bladder cancer	0.000144	0.000435	CcSEcCtD
Zoledronate—Syncope—Doxorubicin—urinary bladder cancer	0.000143	0.000434	CcSEcCtD
Zoledronate—Leukopenia—Doxorubicin—urinary bladder cancer	0.000143	0.000433	CcSEcCtD
Zoledronate—FDPS—Metabolism—RRM2—urinary bladder cancer	0.000143	0.00244	CbGpPWpGaD
Zoledronate—Confusional state—Epirubicin—urinary bladder cancer	0.000142	0.00043	CcSEcCtD
Zoledronate—Palpitations—Doxorubicin—urinary bladder cancer	0.000141	0.000428	CcSEcCtD
Zoledronate—Oedema—Epirubicin—urinary bladder cancer	0.000141	0.000427	CcSEcCtD
Zoledronate—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000141	0.000427	CcSEcCtD
Zoledronate—Hypotension—Methotrexate—urinary bladder cancer	0.000141	0.000426	CcSEcCtD
Zoledronate—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00014	0.000425	CcSEcCtD
Zoledronate—Infection—Epirubicin—urinary bladder cancer	0.00014	0.000424	CcSEcCtD
Zoledronate—Cough—Doxorubicin—urinary bladder cancer	0.000139	0.000422	CcSEcCtD
Zoledronate—Shock—Epirubicin—urinary bladder cancer	0.000139	0.00042	CcSEcCtD
Zoledronate—Convulsion—Doxorubicin—urinary bladder cancer	0.000138	0.000419	CcSEcCtD
Zoledronate—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000138	0.000419	CcSEcCtD
Zoledronate—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000138	0.000418	CcSEcCtD
Zoledronate—Hypertension—Doxorubicin—urinary bladder cancer	0.000138	0.000418	CcSEcCtD
Zoledronate—CA12—Metabolism—RRM2—urinary bladder cancer	0.000138	0.00235	CbGpPWpGaD
Zoledronate—Tachycardia—Epirubicin—urinary bladder cancer	0.000138	0.000417	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000137	0.000416	CcSEcCtD
Zoledronate—GGPS1—Metabolism—PPARG—urinary bladder cancer	0.000137	0.00235	CbGpPWpGaD
Zoledronate—Skin disorder—Epirubicin—urinary bladder cancer	0.000137	0.000415	CcSEcCtD
Zoledronate—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000136	0.000413	CcSEcCtD
Zoledronate—Insomnia—Methotrexate—urinary bladder cancer	0.000136	0.000413	CcSEcCtD
Zoledronate—Chest pain—Doxorubicin—urinary bladder cancer	0.000136	0.000412	CcSEcCtD
Zoledronate—Myalgia—Doxorubicin—urinary bladder cancer	0.000136	0.000412	CcSEcCtD
Zoledronate—Arthralgia—Doxorubicin—urinary bladder cancer	0.000136	0.000412	CcSEcCtD
Zoledronate—Anxiety—Doxorubicin—urinary bladder cancer	0.000136	0.000411	CcSEcCtD
Zoledronate—ABCC1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000135	0.00232	CbGpPWpGaD
Zoledronate—Paraesthesia—Methotrexate—urinary bladder cancer	0.000135	0.00041	CcSEcCtD
Zoledronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000135	0.000409	CcSEcCtD
Zoledronate—CA2—Metabolism—TYMP—urinary bladder cancer	0.000135	0.00231	CbGpPWpGaD
Zoledronate—Discomfort—Doxorubicin—urinary bladder cancer	0.000134	0.000407	CcSEcCtD
Zoledronate—Anorexia—Epirubicin—urinary bladder cancer	0.000134	0.000407	CcSEcCtD
Zoledronate—Dyspnoea—Methotrexate—urinary bladder cancer	0.000134	0.000407	CcSEcCtD
Zoledronate—Somnolence—Methotrexate—urinary bladder cancer	0.000134	0.000406	CcSEcCtD
Zoledronate—Dry mouth—Doxorubicin—urinary bladder cancer	0.000133	0.000403	CcSEcCtD
Zoledronate—Dyspepsia—Methotrexate—urinary bladder cancer	0.000133	0.000402	CcSEcCtD
Zoledronate—FDPS—Metabolism—ENO2—urinary bladder cancer	0.000132	0.00226	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—HPGDS—urinary bladder cancer	0.000132	0.00226	CbGpPWpGaD
Zoledronate—Hypotension—Epirubicin—urinary bladder cancer	0.000132	0.000399	CcSEcCtD
Zoledronate—GGPS1—Metabolism—CREBBP—urinary bladder cancer	0.000132	0.00225	CbGpPWpGaD
Zoledronate—Confusional state—Doxorubicin—urinary bladder cancer	0.000131	0.000398	CcSEcCtD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000131	0.00225	CbGpPWpGaD
Zoledronate—Decreased appetite—Methotrexate—urinary bladder cancer	0.000131	0.000397	CcSEcCtD
Zoledronate—Oedema—Doxorubicin—urinary bladder cancer	0.00013	0.000395	CcSEcCtD
Zoledronate—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00013	0.000395	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00013	0.000394	CcSEcCtD
Zoledronate—Fatigue—Methotrexate—urinary bladder cancer	0.00013	0.000393	CcSEcCtD
Zoledronate—Infection—Doxorubicin—urinary bladder cancer	0.00013	0.000392	CcSEcCtD
Zoledronate—Pain—Methotrexate—urinary bladder cancer	0.000129	0.00039	CcSEcCtD
Zoledronate—ABCC1—Disease—GSTO2—urinary bladder cancer	0.000129	0.0022	CbGpPWpGaD
Zoledronate—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000128	0.000389	CcSEcCtD
Zoledronate—Shock—Doxorubicin—urinary bladder cancer	0.000128	0.000389	CcSEcCtD
Zoledronate—FDPS—Metabolism—GSTT1—urinary bladder cancer	0.000128	0.00219	CbGpPWpGaD
Zoledronate—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000128	0.000387	CcSEcCtD
Zoledronate—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000128	0.000387	CcSEcCtD
Zoledronate—Insomnia—Epirubicin—urinary bladder cancer	0.000127	0.000386	CcSEcCtD
Zoledronate—CA12—Metabolism—HPGDS—urinary bladder cancer	0.000127	0.00218	CbGpPWpGaD
Zoledronate—CA12—Metabolism—ENO2—urinary bladder cancer	0.000127	0.00218	CbGpPWpGaD
Zoledronate—Tachycardia—Doxorubicin—urinary bladder cancer	0.000127	0.000386	CcSEcCtD
Zoledronate—Skin disorder—Doxorubicin—urinary bladder cancer	0.000127	0.000384	CcSEcCtD
Zoledronate—Paraesthesia—Epirubicin—urinary bladder cancer	0.000127	0.000383	CcSEcCtD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000126	0.00216	CbGpPWpGaD
Zoledronate—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000126	0.000382	CcSEcCtD
Zoledronate—Dyspnoea—Epirubicin—urinary bladder cancer	0.000126	0.000381	CcSEcCtD
Zoledronate—Somnolence—Epirubicin—urinary bladder cancer	0.000125	0.00038	CcSEcCtD
Zoledronate—Anorexia—Doxorubicin—urinary bladder cancer	0.000124	0.000377	CcSEcCtD
Zoledronate—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000124	0.000376	CcSEcCtD
Zoledronate—Dyspepsia—Epirubicin—urinary bladder cancer	0.000124	0.000376	CcSEcCtD
Zoledronate—CA12—Metabolism—GSTT1—urinary bladder cancer	0.000124	0.00211	CbGpPWpGaD
Zoledronate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000123	0.000373	CcSEcCtD
Zoledronate—Decreased appetite—Epirubicin—urinary bladder cancer	0.000122	0.000371	CcSEcCtD
Zoledronate—CA14—Metabolism—NQO1—urinary bladder cancer	0.000122	0.00208	CbGpPWpGaD
Zoledronate—CA2—Metabolism—NAT2—urinary bladder cancer	0.000122	0.00208	CbGpPWpGaD
Zoledronate—Hypotension—Doxorubicin—urinary bladder cancer	0.000122	0.000369	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000122	0.000369	CcSEcCtD
Zoledronate—Fatigue—Epirubicin—urinary bladder cancer	0.000121	0.000368	CcSEcCtD
Zoledronate—Pain—Epirubicin—urinary bladder cancer	0.00012	0.000365	CcSEcCtD
Zoledronate—Constipation—Epirubicin—urinary bladder cancer	0.00012	0.000365	CcSEcCtD
Zoledronate—Urticaria—Methotrexate—urinary bladder cancer	0.00012	0.000362	CcSEcCtD
Zoledronate—Abdominal pain—Methotrexate—urinary bladder cancer	0.000119	0.000361	CcSEcCtD
Zoledronate—Body temperature increased—Methotrexate—urinary bladder cancer	0.000119	0.000361	CcSEcCtD
Zoledronate—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000119	0.00036	CcSEcCtD
Zoledronate—Insomnia—Doxorubicin—urinary bladder cancer	0.000118	0.000357	CcSEcCtD
Zoledronate—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000117	0.000355	CcSEcCtD
Zoledronate—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000116	0.000352	CcSEcCtD
Zoledronate—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000116	0.000352	CcSEcCtD
Zoledronate—Somnolence—Doxorubicin—urinary bladder cancer	0.000116	0.000351	CcSEcCtD
Zoledronate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000115	0.000349	CcSEcCtD
Zoledronate—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000115	0.000348	CcSEcCtD
Zoledronate—ABCC1—Metabolism—GSTZ1—urinary bladder cancer	0.000114	0.00194	CbGpPWpGaD
Zoledronate—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000113	0.000343	CcSEcCtD
Zoledronate—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000113	0.000341	CcSEcCtD
Zoledronate—Fatigue—Doxorubicin—urinary bladder cancer	0.000112	0.000341	CcSEcCtD
Zoledronate—Urticaria—Epirubicin—urinary bladder cancer	0.000112	0.000339	CcSEcCtD
Zoledronate—Constipation—Doxorubicin—urinary bladder cancer	0.000111	0.000338	CcSEcCtD
Zoledronate—Pain—Doxorubicin—urinary bladder cancer	0.000111	0.000338	CcSEcCtD
Zoledronate—Body temperature increased—Epirubicin—urinary bladder cancer	0.000111	0.000337	CcSEcCtD
Zoledronate—Abdominal pain—Epirubicin—urinary bladder cancer	0.000111	0.000337	CcSEcCtD
Zoledronate—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000111	0.000336	CcSEcCtD
Zoledronate—Asthenia—Methotrexate—urinary bladder cancer	0.000108	0.000327	CcSEcCtD
Zoledronate—GGPS1—Metabolism—PTGS2—urinary bladder cancer	0.000108	0.00184	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—GSTO2—urinary bladder cancer	0.000108	0.00184	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—NAT1—urinary bladder cancer	0.000108	0.00184	CbGpPWpGaD
Zoledronate—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000107	0.000326	CcSEcCtD
Zoledronate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000107	0.000323	CcSEcCtD
Zoledronate—Pruritus—Methotrexate—urinary bladder cancer	0.000107	0.000323	CcSEcCtD
Zoledronate—FDPS—Metabolism—NQO1—urinary bladder cancer	0.000107	0.00182	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000106	0.00181	CbGpPWpGaD
Zoledronate—CA2—Metabolism—RRM2—urinary bladder cancer	0.000105	0.0018	CbGpPWpGaD
Zoledronate—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000104	0.000315	CcSEcCtD
Zoledronate—Urticaria—Doxorubicin—urinary bladder cancer	0.000104	0.000314	CcSEcCtD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000103	0.00177	CbGpPWpGaD
Zoledronate—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000103	0.000312	CcSEcCtD
Zoledronate—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000103	0.000312	CcSEcCtD
Zoledronate—Diarrhoea—Methotrexate—urinary bladder cancer	0.000103	0.000312	CcSEcCtD
Zoledronate—CA12—Metabolism—NQO1—urinary bladder cancer	0.000103	0.00176	CbGpPWpGaD
Zoledronate—CA14—Metabolism—GSTP1—urinary bladder cancer	0.000102	0.00174	CbGpPWpGaD
Zoledronate—Asthenia—Epirubicin—urinary bladder cancer	0.000101	0.000306	CcSEcCtD
Zoledronate—ABCC1—Disease—SLC19A1—urinary bladder cancer	0.0001	0.00171	CbGpPWpGaD
Zoledronate—Pruritus—Epirubicin—urinary bladder cancer	9.97e-05	0.000302	CcSEcCtD
Zoledronate—Dizziness—Methotrexate—urinary bladder cancer	9.96e-05	0.000302	CcSEcCtD
Zoledronate—ABCC1—Metabolism—UGT2B7—urinary bladder cancer	9.85e-05	0.00168	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PRSS3—urinary bladder cancer	9.74e-05	0.00167	CbGpPWpGaD
Zoledronate—CA2—Metabolism—HPGDS—urinary bladder cancer	9.74e-05	0.00167	CbGpPWpGaD
Zoledronate—CA2—Metabolism—ENO2—urinary bladder cancer	9.74e-05	0.00167	CbGpPWpGaD
Zoledronate—Diarrhoea—Epirubicin—urinary bladder cancer	9.64e-05	0.000292	CcSEcCtD
Zoledronate—Hypersensitivity—Doxorubicin—urinary bladder cancer	9.61e-05	0.000291	CcSEcCtD
Zoledronate—Vomiting—Methotrexate—urinary bladder cancer	9.57e-05	0.00029	CcSEcCtD
Zoledronate—Rash—Methotrexate—urinary bladder cancer	9.49e-05	0.000288	CcSEcCtD
Zoledronate—Dermatitis—Methotrexate—urinary bladder cancer	9.49e-05	0.000287	CcSEcCtD
Zoledronate—CA2—Metabolism—GSTT1—urinary bladder cancer	9.45e-05	0.00162	CbGpPWpGaD
Zoledronate—CA14—Metabolism—TYMS—urinary bladder cancer	9.45e-05	0.00162	CbGpPWpGaD
Zoledronate—Headache—Methotrexate—urinary bladder cancer	9.43e-05	0.000286	CcSEcCtD
Zoledronate—GGPS1—Metabolism—PTEN—urinary bladder cancer	9.4e-05	0.00161	CbGpPWpGaD
Zoledronate—Asthenia—Doxorubicin—urinary bladder cancer	9.35e-05	0.000283	CcSEcCtD
Zoledronate—CA14—Metabolism—GSTM1—urinary bladder cancer	9.34e-05	0.0016	CbGpPWpGaD
Zoledronate—CA14—Metabolism—NCOR1—urinary bladder cancer	9.34e-05	0.0016	CbGpPWpGaD
Zoledronate—Dizziness—Epirubicin—urinary bladder cancer	9.32e-05	0.000282	CcSEcCtD
Zoledronate—ABCC1—Disease—HDAC4—urinary bladder cancer	9.29e-05	0.00159	CbGpPWpGaD
Zoledronate—Pruritus—Doxorubicin—urinary bladder cancer	9.22e-05	0.000279	CcSEcCtD
Zoledronate—ABCC1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	9.15e-05	0.00157	CbGpPWpGaD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.01e-05	0.00154	CbGpPWpGaD
Zoledronate—GGPS1—Metabolism—EP300—urinary bladder cancer	8.97e-05	0.00153	CbGpPWpGaD
Zoledronate—Vomiting—Epirubicin—urinary bladder cancer	8.96e-05	0.000271	CcSEcCtD
Zoledronate—CA14—Metabolism—GPX1—urinary bladder cancer	8.94e-05	0.00153	CbGpPWpGaD
Zoledronate—Nausea—Methotrexate—urinary bladder cancer	8.94e-05	0.000271	CcSEcCtD
Zoledronate—Diarrhoea—Doxorubicin—urinary bladder cancer	8.92e-05	0.00027	CcSEcCtD
Zoledronate—Rash—Epirubicin—urinary bladder cancer	8.88e-05	0.000269	CcSEcCtD
Zoledronate—FDPS—Metabolism—GSTP1—urinary bladder cancer	8.88e-05	0.00152	CbGpPWpGaD
Zoledronate—Dermatitis—Epirubicin—urinary bladder cancer	8.88e-05	0.000269	CcSEcCtD
Zoledronate—ABCC1—Metabolism—CYP4B1—urinary bladder cancer	8.87e-05	0.00152	CbGpPWpGaD
Zoledronate—Headache—Epirubicin—urinary bladder cancer	8.83e-05	0.000267	CcSEcCtD
Zoledronate—CA14—Metabolism—ERCC2—urinary bladder cancer	8.78e-05	0.0015	CbGpPWpGaD
Zoledronate—Dizziness—Doxorubicin—urinary bladder cancer	8.62e-05	0.000261	CcSEcCtD
Zoledronate—FDPS—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.59e-05	0.00147	CbGpPWpGaD
Zoledronate—CA12—Metabolism—GSTP1—urinary bladder cancer	8.57e-05	0.00147	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—SLC19A1—urinary bladder cancer	8.37e-05	0.00143	CbGpPWpGaD
Zoledronate—Nausea—Epirubicin—urinary bladder cancer	8.37e-05	0.000254	CcSEcCtD
Zoledronate—Vomiting—Doxorubicin—urinary bladder cancer	8.29e-05	0.000251	CcSEcCtD
Zoledronate—FDPS—Metabolism—TYMS—urinary bladder cancer	8.26e-05	0.00141	CbGpPWpGaD
Zoledronate—CA14—Metabolism—MTHFR—urinary bladder cancer	8.25e-05	0.00141	CbGpPWpGaD
Zoledronate—Rash—Doxorubicin—urinary bladder cancer	8.22e-05	0.000249	CcSEcCtD
Zoledronate—Dermatitis—Doxorubicin—urinary bladder cancer	8.21e-05	0.000249	CcSEcCtD
Zoledronate—Headache—Doxorubicin—urinary bladder cancer	8.17e-05	0.000247	CcSEcCtD
Zoledronate—FDPS—Metabolism—NCOR1—urinary bladder cancer	8.16e-05	0.0014	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—GSTM1—urinary bladder cancer	8.16e-05	0.0014	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PRSS3—urinary bladder cancer	8.16e-05	0.0014	CbGpPWpGaD
Zoledronate—CA12—Metabolism—TYMS—urinary bladder cancer	7.96e-05	0.00136	CbGpPWpGaD
Zoledronate—CA12—Metabolism—NCOR1—urinary bladder cancer	7.87e-05	0.00135	CbGpPWpGaD
Zoledronate—CA12—Metabolism—GSTM1—urinary bladder cancer	7.87e-05	0.00135	CbGpPWpGaD
Zoledronate—CA2—Metabolism—NQO1—urinary bladder cancer	7.85e-05	0.00134	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—GPX1—urinary bladder cancer	7.82e-05	0.00134	CbGpPWpGaD
Zoledronate—Nausea—Doxorubicin—urinary bladder cancer	7.74e-05	0.000235	CcSEcCtD
Zoledronate—FDPS—Metabolism—ERCC2—urinary bladder cancer	7.68e-05	0.00131	CbGpPWpGaD
Zoledronate—CA12—Metabolism—GPX1—urinary bladder cancer	7.54e-05	0.00129	CbGpPWpGaD
Zoledronate—CA12—Metabolism—ERCC2—urinary bladder cancer	7.4e-05	0.00127	CbGpPWpGaD
Zoledronate—ABCC1—Disease—LIG1—urinary bladder cancer	7.38e-05	0.00126	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—MTHFR—urinary bladder cancer	7.21e-05	0.00123	CbGpPWpGaD
Zoledronate—CA12—Metabolism—MTHFR—urinary bladder cancer	6.96e-05	0.00119	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PPARG—urinary bladder cancer	6.69e-05	0.00115	CbGpPWpGaD
Zoledronate—CA2—Metabolism—GSTP1—urinary bladder cancer	6.55e-05	0.00112	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.54e-05	0.00112	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—TYMP—urinary bladder cancer	6.52e-05	0.00112	CbGpPWpGaD
Zoledronate—CA14—Metabolism—CREBBP—urinary bladder cancer	6.43e-05	0.0011	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.26e-05	0.00107	CbGpPWpGaD
Zoledronate—CA2—Metabolism—TYMS—urinary bladder cancer	6.09e-05	0.00104	CbGpPWpGaD
Zoledronate—CA2—Metabolism—NCOR1—urinary bladder cancer	6.02e-05	0.00103	CbGpPWpGaD
Zoledronate—CA2—Metabolism—GSTM1—urinary bladder cancer	6.02e-05	0.00103	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—NAT2—urinary bladder cancer	5.9e-05	0.00101	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PPARG—urinary bladder cancer	5.85e-05	0.001	CbGpPWpGaD
Zoledronate—CA2—Metabolism—GPX1—urinary bladder cancer	5.76e-05	0.000986	CbGpPWpGaD
Zoledronate—CA2—Metabolism—ERCC2—urinary bladder cancer	5.66e-05	0.000968	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PPARG—urinary bladder cancer	5.64e-05	0.000965	CbGpPWpGaD
Zoledronate—ABCC1—Disease—ENO2—urinary bladder cancer	5.63e-05	0.000963	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—CREBBP—urinary bladder cancer	5.62e-05	0.000962	CbGpPWpGaD
Zoledronate—CA12—Metabolism—CREBBP—urinary bladder cancer	5.42e-05	0.000927	CbGpPWpGaD
Zoledronate—ABCC1—Disease—RBX1—urinary bladder cancer	5.34e-05	0.000913	CbGpPWpGaD
Zoledronate—CA2—Metabolism—MTHFR—urinary bladder cancer	5.32e-05	0.00091	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PTGS2—urinary bladder cancer	5.27e-05	0.000901	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—RRM2—urinary bladder cancer	5.09e-05	0.000871	CbGpPWpGaD
Zoledronate—ABCC1—Disease—JAG1—urinary bladder cancer	4.78e-05	0.000817	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—HPGDS—urinary bladder cancer	4.72e-05	0.000807	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—ENO2—urinary bladder cancer	4.72e-05	0.000807	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.69e-05	0.000802	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PTGS2—urinary bladder cancer	4.6e-05	0.000787	CbGpPWpGaD
Zoledronate—CA14—Metabolism—PTEN—urinary bladder cancer	4.59e-05	0.000786	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—GSTT1—urinary bladder cancer	4.57e-05	0.000783	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.5e-05	0.000771	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PTGS2—urinary bladder cancer	4.44e-05	0.000759	CbGpPWpGaD
Zoledronate—CA14—Metabolism—EP300—urinary bladder cancer	4.38e-05	0.000749	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PPARG—urinary bladder cancer	4.31e-05	0.000738	CbGpPWpGaD
Zoledronate—ABCC1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.28e-05	0.000733	CbGpPWpGaD
Zoledronate—CA2—Metabolism—CREBBP—urinary bladder cancer	4.14e-05	0.000709	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—PTEN—urinary bladder cancer	4.01e-05	0.000687	CbGpPWpGaD
Zoledronate—CA12—Metabolism—PTEN—urinary bladder cancer	3.87e-05	0.000662	CbGpPWpGaD
Zoledronate—FDPS—Metabolism—EP300—urinary bladder cancer	3.83e-05	0.000655	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—NQO1—urinary bladder cancer	3.8e-05	0.00065	CbGpPWpGaD
Zoledronate—CA12—Metabolism—EP300—urinary bladder cancer	3.69e-05	0.000632	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.69e-05	0.000631	CbGpPWpGaD
Zoledronate—ABCC1—Disease—NCOR1—urinary bladder cancer	3.48e-05	0.000595	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PTGS2—urinary bladder cancer	3.39e-05	0.000581	CbGpPWpGaD
Zoledronate—ABCC1—Disease—ERCC2—urinary bladder cancer	3.27e-05	0.00056	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.22e-05	0.00055	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—GSTP1—urinary bladder cancer	3.17e-05	0.000542	CbGpPWpGaD
Zoledronate—ABCC1—Disease—MTHFR—urinary bladder cancer	3.07e-05	0.000526	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.07e-05	0.000525	CbGpPWpGaD
Zoledronate—ABCC1—Disease—TERT—urinary bladder cancer	3.07e-05	0.000525	CbGpPWpGaD
Zoledronate—CA2—Metabolism—PTEN—urinary bladder cancer	2.96e-05	0.000506	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—TYMS—urinary bladder cancer	2.95e-05	0.000504	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—NCOR1—urinary bladder cancer	2.91e-05	0.000498	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—GSTM1—urinary bladder cancer	2.91e-05	0.000498	CbGpPWpGaD
Zoledronate—CA2—Metabolism—EP300—urinary bladder cancer	2.82e-05	0.000483	CbGpPWpGaD
Zoledronate—ABCC1—Disease—FGFR3—urinary bladder cancer	2.81e-05	0.000481	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—GPX1—urinary bladder cancer	2.79e-05	0.000477	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—ERCC2—urinary bladder cancer	2.74e-05	0.000469	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—MTHFR—urinary bladder cancer	2.57e-05	0.000441	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CREBBP—urinary bladder cancer	2.4e-05	0.00041	CbGpPWpGaD
Zoledronate—ABCC1—Disease—RHOA—urinary bladder cancer	2.17e-05	0.000371	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PPARG—urinary bladder cancer	2.09e-05	0.000357	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—CREBBP—urinary bladder cancer	2.01e-05	0.000343	CbGpPWpGaD
Zoledronate—ABCC1—Disease—ERBB2—urinary bladder cancer	2.01e-05	0.000343	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PTGS2—urinary bladder cancer	1.96e-05	0.000336	CbGpPWpGaD
Zoledronate—ABCC1—Disease—CDKN1A—urinary bladder cancer	1.71e-05	0.000293	CbGpPWpGaD
Zoledronate—ABCC1—Disease—PTEN—urinary bladder cancer	1.71e-05	0.000293	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PTGS2—urinary bladder cancer	1.64e-05	0.000281	CbGpPWpGaD
Zoledronate—ABCC1—Disease—EP300—urinary bladder cancer	1.63e-05	0.000279	CbGpPWpGaD
Zoledronate—ABCC1—Disease—SRC—urinary bladder cancer	1.59e-05	0.000271	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—PTEN—urinary bladder cancer	1.43e-05	0.000245	CbGpPWpGaD
Zoledronate—ABCC1—Disease—MYC—urinary bladder cancer	1.42e-05	0.000243	CbGpPWpGaD
Zoledronate—ABCC1—Disease—EGFR—urinary bladder cancer	1.39e-05	0.000238	CbGpPWpGaD
Zoledronate—ABCC1—Metabolism—EP300—urinary bladder cancer	1.37e-05	0.000234	CbGpPWpGaD
Zoledronate—ABCC1—Disease—KRAS—urinary bladder cancer	1.31e-05	0.000225	CbGpPWpGaD
Zoledronate—ABCC1—Disease—HRAS—urinary bladder cancer	1.12e-05	0.000191	CbGpPWpGaD
